<DOC>
	<DOCNO>NCT00197587</DOCNO>
	<brief_summary>The purpose study find effective safe treatment prevent passage HIV infect mother baby .</brief_summary>
	<brief_title>Prevention Milk-Borne Transmission HIV-1C Botswana</brief_title>
	<detailed_description>1 . To assess effectiveness addition single dose nevirapine ( NVP ) Zidovudine ( ZDV , also know AZT ) use Botswana mother-to-child transmission ( MTCT ) National Program , reduce transmission HIV-1 mother child . To determine maternal NVP ( per HIVNET 012 protocol ) necessary set maternal ZDV 34 week gestation delivery AND single-dose prophylactic infant NVP birth plus ZDV birth 4 week reduction transmission HIV-1 mother child . 2 . To assess effect prophylactic AZT give infant breast feed HIV transmission . 3 . To confirm safety tolerance one dose NVP give mother infant 4 . To evaluate safety tolerance AZT give infant 6 month age 5 . To determine association assign infant feeding strategy maternal morbidity mortality 6 . To determine rate virologic response NNRTI-containing HAART 26 52 week initiate treatment , among HIV+ woman previously receive single dose NVP versus placebo labour .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>Nevirapine</mesh_term>
	<criteria>Mothers must 34 week pregnant , intend carry term , intend stay area least 7 month , consent HIV1 test participation ; HIV1 infect ELISA confirm Western blot ; etc .</criteria>
	<gender>Female</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>May 2013</verification_date>
</DOC>